Completed PHASE2 INTERVENTIONAL 1-arm NCT00002676

Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma

PHASE II TRIAL OF CHEMOTHERAPY PLUS RADIOTHERAPY FOR MANAGEMENT OF PRIMARY CENTRAL NERVOUS SYSTEM NON-HODGKIN'S LYMPHOMA (PCNSL)

Sponsor: Alliance for Clinical Trials in Oncology

Conditions Lymphoma

Interventions carmustine cyclophosphamide cytarabine dexamethasone doxorubicin hydrochloride low-LET cobalt-60 gamma ray therapy low-LET photon therapy methotrexate vincristine sulfate

Updated 7 times since 2017 Last updated: Jul 12, 2016 Started: Jul 31, 1995 Primary completion: Oct 31, 2006 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lymphoma and is currently completed. Alliance for Clinical Trials in Oncology leads this study, which shows 7 recorded versions since 1995 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Study Description(click to expand)

OBJECTIVES: I. Assess the response to CHOD (cyclophosphamide/doxorubicin/vincristine/ dexamethasone) and BVAM (carmustine/vincristine/cytarabine/methotrexate) plus whole-brain radiotherapy in patients with primary central nervous system non-Hodgkin's lymphoma (PCNSL). II. Assess the toxic effects associated with this treatment. III. Assess the survival of patients with PCNSL receiving this treatment. IV. Investigate the frequency of systemic involvement at follow-up. V. Identify factors that appear to be associated with outcome.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bismarck, United States , Cedar Rapids, United States , Columbus, United States , Denver, United States , Des Moines, United States , Duluth, United States , Grand Forks, United States , Hackensack, United States , Kalamazoo, United States , New Orleans, United States and 11 more locations